214 related articles for article (PubMed ID: 36882627)
41. Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: A systematic review with meta-analysis.
Wei C; Du X; Hu J; Dong Y; Chen Y; Cao B
Crit Rev Oncol Hematol; 2024 Jun; 198():104082. PubMed ID: 37532103
[TBL] [Abstract][Full Text] [Related]
42. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
[TBL] [Abstract][Full Text] [Related]
43. Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis.
Bradley A; Van Der Meer R
Sci Rep; 2019 Mar; 9(1):4354. PubMed ID: 30867522
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
Yang Z; Jiang X
BMC Gastroenterol; 2023 Apr; 23(1):122. PubMed ID: 37046191
[TBL] [Abstract][Full Text] [Related]
45. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
[TBL] [Abstract][Full Text] [Related]
46. Upfront surgery vs. neoadjuvant therapy for resectable pancreatic cancer: a narrative review of available evidence.
Ratnayake CBB; Roberts KJ; Pandanaboyana S
Chin Clin Oncol; 2022 Feb; 11(1):2. PubMed ID: 35184565
[TBL] [Abstract][Full Text] [Related]
47. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
48. Postoperative adjuvant chemotherapy in rectal cancer operated for cure.
Petersen SH; Harling H; Kirkeby LT; Wille-Jørgensen P; Mocellin S
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD004078. PubMed ID: 22419291
[TBL] [Abstract][Full Text] [Related]
49. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer.
Urschel JD; Vasan H
Am J Surg; 2003 Jun; 185(6):538-43. PubMed ID: 12781882
[TBL] [Abstract][Full Text] [Related]
50. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
[TBL] [Abstract][Full Text] [Related]
51. A systematic overview of chemotherapy effects in gastric cancer.
Janunger KG; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):309-26. PubMed ID: 11441938
[TBL] [Abstract][Full Text] [Related]
52. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer.
Yan TD; Black D; Sugarbaker PH; Zhu J; Yonemura Y; Petrou G; Morris DL
Ann Surg Oncol; 2007 Oct; 14(10):2702-13. PubMed ID: 17653801
[TBL] [Abstract][Full Text] [Related]
53. A systematic review and network meta-analysis of randomised controlled trials comparing neoadjuvant treatment strategies for stage II and III rectal cancer.
Simillis C; Khatri A; Dai N; Afxentiou T; Jephcott C; Smith S; Jadon R; Papamichael D; Khan J; Powar MP; Fearnhead NS; Wheeler J; Davies J
Crit Rev Oncol Hematol; 2023 Mar; 183():103927. PubMed ID: 36706968
[TBL] [Abstract][Full Text] [Related]
54. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
[TBL] [Abstract][Full Text] [Related]
56. A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer.
Ozer M; Goksu SY; Sanford NN; Porembka M; Khurshid H; Ahn C; Maxwell MC; Beg MS; Kazmi SM
JAMA Netw Open; 2022 Feb; 5(2):e2146912. PubMed ID: 35171262
[TBL] [Abstract][Full Text] [Related]
57. Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis.
Gosavi R; Chia C; Michael M; Heriot AG; Warrier SK; Kong JC
Int J Colorectal Dis; 2021 Oct; 36(10):2063-2070. PubMed ID: 33945007
[TBL] [Abstract][Full Text] [Related]
58. The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
Wang T; Li C; Li X; Zhai J; Wang S; Shen L
Eur J Med Res; 2022 Nov; 27(1):239. PubMed ID: 36352476
[TBL] [Abstract][Full Text] [Related]
59. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis.
Yang Y; Yin X; Sheng L; Xu S; Dong L; Liu L
Sci Rep; 2015 Aug; 5():12850. PubMed ID: 26242393
[TBL] [Abstract][Full Text] [Related]
60. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
